Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

141.62 +0.55 (+0.39%)
Streaming Delayed Price Updated: 9:56 AM EDT, Jul 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage
From Natera, Inc.
Via Business Wire
Looking Into Natera's Recent Short Interest
 
Via Benzinga
Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications
From Natera, Inc.
Via Business Wire
Cracking The Code: Understanding Analyst Reviews For Natera
 
Via Benzinga
Looking Into Natera's Recent Short Interest
 
Via Benzinga
Natera Inc. (NASDAQ: NTRA) Records 52-Week High Friday Morning
Via Investor Brand Network
Recap: Natera Q4 Earnings
 
Via Benzinga
Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
From Natera, Inc.
Via Business Wire
Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients
From Natera, Inc.
Via Business Wire
Earnings Preview For Natera
 
Via Benzinga
A Glimpse Into The Expert Outlook On Natera Through 9 Analysts
 
Via Benzinga
There are signs that NASDAQ:NTRA may be ready to breakout.
NATERA INC (NASDAQ:NTRA) has a good technical rating of 10 out of 10 and could possibly break out. 
Via Chartmill
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
From Natera, Inc.
Via Business Wire
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
From Natera, Inc.
Via Business Wire
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
From Natera, Inc.
Via Business Wire
New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease
From Natera, Inc.
Via Business Wire
Disney, Natera, Chubb And A Major Tech Stock On CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Amy Raskin of Chevy Chase Trust said Natera, Inc. 
Via Benzinga
Natera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers
From Natera, Inc.
Via Business Wire
9 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Natera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS Plan
From Natera, Inc.
Via Business Wire
Agilent Technologies Stock Getting Closer To Key Technical Benchmark
Agilent Technologies stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 65 to 71. 
Via Investor's Business Daily
Wall Street Takes A Breather As Inflation Stays Tamed, AMD Hits Record Highs, Apple Struggles: What's Driving Markets Thursday?
Wall Street exhaled a sigh of relief as the Federal Reserve’s favored gauge of inflation cooled as anticipated in January, quelling fears that an unexpected rise in the Consumer Price Index (CPI) might... 
Via Benzinga
Topics Economy
Natera to Participate in March Investor Conferences
From Natera, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Natera Reports Fourth Quarter and Full Year 2023 Financial Results
From Natera, Inc.
Via Business Wire
Cathie Wood's Ark Invest Sheds $9.3M Worth Of Coinbase Shares Amid Bitcoin Rally — Robinhood Stock Also Sold
On Tuesday, Cathie Wood-led Ark Invest adjusted its portfolio, making significant trades. 
Via Benzinga
Earnings Scheduled For February 28, 2024
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion. 
Via Benzinga
Natera Announces Next Phase of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure Tests
From Natera, Inc.
Via Business Wire
Medicare Extends Coverage of Natera’s Signatera™ MRD Test to Ovarian Cancer and Neoadjuvant Breast Cancer
From Natera, Inc.
Via Business Wire
Natera Announces Fourth Quarter and Fiscal 2023 Earnings Conference Call
From Natera, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.